Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide has a half-life of roughly seven days, meaning it takes around five weeks after your final dose for the medicine to clear your system almost entirely. That long half-life is precisely why a once-weekly injection works — levels stay high enough between doses to keep appetite suppressed and gastric emptying slowed throughout the week. As a prescription-only medicine, semaglutide must be assessed and prescribed by a qualified clinician before you start; it is not suitable for everyone, and the right dose and duration are decided case by case.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most medicines leave the body within hours. Semaglutide is engineered to behave differently. It is a modified version of GLP-1, a gut hormone the body produces naturally, but its structure has been altered so that enzymes cannot break it down quickly and it binds tightly to albumin, a protein in the blood. That binding shields it from the kidneys and from the enzymes that would normally clear it. The result is a half-life of around seven days — long enough that a single weekly injection sustains therapeutic blood levels without the peaks and troughs you would see with a daily medicine.
Plasma concentration reaches its peak roughly one to three days after each injection, then falls gradually until the next dose tops it up. After several weeks of weekly dosing, the medicine reaches a steady state: the amount entering the body each week roughly equals the amount being cleared. That steady state is typically reached after four to five weeks of consistent dosing, which is part of why effects tend to build over the first month or two of treatment rather than arriving immediately.
If you want a closer look at what happens in that early build-up period, the page on how long semaglutide takes to get into your system covers that window in detail.
Once you take your last dose, the seven-day half-life means roughly half the remaining medicine is cleared in a week, half of that in the next week, and so on. In practical terms, it takes approximately four to five half-lives (so four to five weeks) for semaglutide to fall to negligible levels, and if you want a fuller picture of that clearance process, the page on how long semaglutide will stay in your system walks through the pharmacokinetics in more detail. Some pharmacokinetic data suggest trace amounts persist slightly longer, but for most people the medicine is effectively gone within five weeks of the final injection.
The effects you notice will fade before the medicine has fully cleared. Appetite suppression tends to ease within one to two weeks of the last injection as levels drop below the threshold needed to maintain that effect meaningfully. Gastric emptying gradually returns to its pre-treatment pace over a similar timeframe. This is why some people find hunger returning fairly quickly after stopping, even though the medicine itself is still technically present in small amounts.
For a more detailed breakdown specific to Wegovy, the page on how long Wegovy stays in your system goes further on the clearance timeline. And if you are curious about the clinical evidence behind what semaglutide achieves during treatment, the Wegovy study results page summarises the key trial data, including the STEP 1 findings published in the New England Journal of Medicine.
The day of the week you inject is less important than keeping it consistent. Because the half-life is so long relative to the dosing interval, missing a dose by a day or two has a smaller proportional impact on blood levels than it would with a short-acting medicine. That said, it still matters, clinical guidance is to take semaglutide on the same day each week where possible. If you miss a dose by more than five days, the Patient Information Leaflet (available via the NHS semaglutide medicines page) advises skipping it and resuming on your usual schedule the following week.
Some practical timing considerations come up regularly. People who travel, or who order treatment around payday or the start of a new month, sometimes ask whether a brief gap matters. Given the long half-life, a few days' delay is less disruptive than it feels, but longer interruptions should be discussed with your prescriber before you resume. Dose changes, in particular, always need a clinical review first, our prescribers at nume review every repeat order before it is dispensed, so there is always a clinical check built in.
If your broader question is about how quickly you can expect to see results rather than clearance timescales, the page on how long Wegovy takes to work is the more relevant read. Cost context, for anyone weighing up whether a private prescription makes sense, is covered on our Wegovy pricing page.
This is the question most people are really asking. Semaglutide does not permanently alter your metabolism. Once it clears, the underlying biology that drove appetite and weight gain before treatment tends to reassert itself. Clinical trial follow-up data show that, without ongoing treatment or sustained lifestyle changes, a meaningful proportion of the weight lost during treatment is regained over the year or two after stopping.
That is not a reason to avoid treatment. It is a reason to think about it as part of a longer plan rather than a short course. The NHS semaglutide guidance, alongside NICE's assessment of Wegovy (TA875), frames these medicines within a broader programme of dietary and activity support rather than as standalone fixes. Stopping, continuing, or switching are all clinical decisions that belong in a conversation with a prescriber, not a read of a clearance chart. If you are at the point of weighing your options, speaking to our prescribers is the natural next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.